Dong-A Progresses In Diabetes With Lat Am Deal, New Study
This article was originally published in PharmAsia News
With the global diabetes treatment market expected to show continued growth, South Korea's Dong-A ST is making progress in the sector by signing an additional licensing out contract for its new drug and successfully completing a Phase II U.S. study with a potential diabetic neuropathy therapy.
You may also be interested in...
Dong-A makes notable progress in botanical drug programs, reaching deals for its diabetic neuropathic pain and Alzheimer's disease drug assets with Boston-based NeuroBo Pharmaceuticals.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.